Besides, with an increasing number of studies aimed at metabolism regulation in renal carcinoma [21–24], we are looking forward to a new therapeutic strategy for ccRCC by utilizing METTL13’s potential participation in metabolism, including METTL13’s inhibitory impact on expressions of metabolism-related genes, HIF-1α and c-Myc. This evidence concerns the gene METTL13 and nonpapillary renal cell carcinoma.